Pharma BD Deal Intelligence
Sanofi's $4.0B 2009 buyout of Merck's Merial stake looked like a strategic bet on animal health, and it worked operationally—sales grew from roughly €2.0B to over €2.5B by 2015. But Sanofi swapped the entire business to Boehringer Ingelheim in 2016 for BI's Consumer Healthcare unit plus €4.7B cash, meaning it ended up owning none of the asset it originally bought.
Sanofi bought out Merck's Merial stake for $4B in 2009, grew it into a full animal-health unit worth an implied ~€11.4B by 2016, then swapped the entire business away to Boehringer Ingelheim for BI's Consumer Healthcare unit plus €4.7B cash — a financially strong exit but a full strategic reversal, since Sanofi no longer owns any of the asset it bought.
Full analysis, sources & comparables →Merck CEO Richard Clark: 'These agreements should enable us to proceed expeditiously with the closing of our merger with Schering-Plough in the fourth quarter…
Merck will sell its 50 percent interest in the companies' current animal health joint venture, Merial Limited (Merial), to sanofi-aventis for $4 billion (US)…
C&EN reported the abandonment of the Merial-Intervet recombination, framing the 2009 Sanofi buyout as still strategically sound for Sanofi's diversification…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
$4B cash for Merck's 50% stake in animal health JV. Animal health (note: borderline pharma but veterinary therapeutics). Source: Pharma Times, Modern Healthcare, AVMA.
Sanofi bought out Merck's Merial stake for $4B in 2009, grew it into a full animal-health unit worth an implied ~€11.4B by 2016, then swapped the entire business away to Boehringer Ingelheim for BI's Consumer Healthcare unit plus €4.7B cash — a financially strong exit but a full strategic reversal, since Sanofi no longer owns any of the asset it bought.
Assessment window: 15yr post-close.
$19.0B Global animal health market 2009 (per Sanofi CEO)
Animal health spans companion-animal parasiticides and vaccines plus livestock vaccines, antibiotics and feed-additive therapeutics. The category sits adjacent to pharma but follows different regulatory (USDA/CVM/EMA-CVMP) and channel economics (vet-distributed and retail). In 2008, Merial generated approximately €2 billion in revenue with leading franchises in flea/tick (Frontline) and heartworm prevention (Heartgard).
At the time of Sanofi's $4B buy-in for Merck's 50% Merial stake, the global animal health market was approximately $19B and led by a tight set: Pfizer Animal Health (later spun out as Zoetis in 2013), Merial (Sanofi/Merck JV since 1997), Intervet/Schering-Plough Animal Health, Bayer Animal Health, Boehringer Ingelheim Vetmedica, Elanco (Eli Lilly), and Novartis Animal Health. Merial's marquee franchises were Frontline (fipronil) for fleas/ticks and Heartgard (ivermectin) for heartworm; competitors included Bayer's Advantage/Advantix and Novartis's Sentinel. Sanofi paid 3.0x 2008 sales and 10.2x 2008 EBIT, with the deal forced by Merck's need to clear antitrust hurdles for its Schering-Plough merger. The original plan to recombine Merial with Intervet/Schering-Plough was abandoned in March 2011 due to 'increasing complexity' of divestiture and regulatory review. Sanofi later swapped Merial to Boehringer Ingelheim in 2017 for BI's consumer health unit. Sources: https://pharmatimes.com/news/sanofi_buys_mercks_50_merial_stake,_intervet_linked_planned_983925/ and https://www.merck.com/news/merck-and-sanofi-aventis-to-maintain-separate-businesses-in-animal-health/
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi-Aventis / Merial Limited (Merck's 50% interest) (this deal) | 2009 | $4.0B | 65 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Sanofi-Aventis / Acambis plc | 2008 | $548M | 36 |
| Sanofi-Aventis / Shantha Biotechnics Limited | 2009 | $784M | 34 |
| Sanofi-Aventis / Fovea Pharmaceuticals SA | 2009 | $541M | 23 |
| Sanofi-Aventis / BiPar Sciences, Inc. | 2009 | $500M | 8 |
| Sanofi-Aventis / ImmunoGen Inc. | 2005 | $18M | — |
← Browse all deals · How we score deals
More: 2009 deals · Sanofi-Aventis deals